← Leaderboards
Mark B Geyer
Actinium Pharmaceuticals, Inc.
$1,255,803
Attributed
$2,511,605
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $865.3K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,511,605 · 2
By mechanism
R42$2,109,005 · 1
R01$402,600 · 1
Top collaborators
- Avinash Desai2 shared
- Mark S Berger1 shared
- Anthony Folawuyi Daniyan1 shared
Most similar at Actinium Pharmaceuticals, Inc.
Same institution · by research overlap
- Avinash Desai$865,308
- Mark S Berger$189,195
Others in their field
Other Emerging Leaders on “Pre-Clinical Model”
- Leonard Freedman · Leidos Biomedical Research, Inc.$255,997,443
- Lynn Briscoe · Leidos Biomedical Research, Inc.$95,451,222
- Ted Ross · University Of Georgia$68,763,143
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Prasant Mohapatra · University Of California At Davis$39,700,992
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$31,987,151
Research focus
Pre-Clinical ModelAntibodiesImmunotherapySafetyCytokineAcute Myelocytic LeukemiaHematopoieticImmuneT Cell TherapyTumorCellsBehavior TherapyAgedBiodistributionB-Cell Acute Lymphoblastic LeukemiaAutologousAdultActiniumCd19 AntigensAdoptive Cell TransfersCancer CellCd19 GeneCd28 GeneAntibody-Drug Conjugates
Grant awards (4)
Development of chimeric antigen receptor T cells targeting cell surface U5 snRNP for the treatment of acute myeloid leukemia$402,600
R01 · FY2025 · CA
Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL$865,308
R42 · FY2024 · CA
Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL$865,308
R42 · FY2023 · CA
Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL$378,389
R42 · FY2020 · CA